Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

非小细胞肺癌的驱动基因EGFR有个不是很常见的突变位点——20号外显子插入突变，这个突变类型占所有EGFR突变的6%左右，使用第一代和第二代EGFR靶向药治疗EGFR基因的20外显子插入突变，治疗应答率仅为10%左右，中位无进展生存时间大概为1到3个 ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

In this video, Xiuning Le, MD, PhD, discusses the greatest areas of unmet need in the treatment of EGFR-mutated lung cancer.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Women have a higher likelihood of having hormone receptor (HR+) non-small cell lung cancer (NSCLC) than men, and mutations of EGFR and KRAS were more common in HR+ NSCLC in a recent study.

Explore how genetic testing and precision oncology are revolutionizing cancer treatment by offering personalized care and ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...